The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation

Genome Medicine

Volumn 8, Issue 1, 2016, Pages

  Langdon, Amy ^a   Crook, Nathan ^a   Dantas, Gautam ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLARITHROMYCIN PLUS METRONIDAZOLE; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; MEROPENEM; METRONIDAZOLE; PROBIOTIC AGENT; STREPTOMYCIN; TICARCILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULTHOOD; ANTIBIOTIC RESISTANCE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL VIRULENCE; BIOLOGICAL THERAPY; BIRTH; CHILDHOOD; CLOSTRIDIUM DIFFICILE INFECTION; DIABETES MELLITUS; DRUG USE; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTESTINE FLORA; MALNUTRITION; MATURATION; MICROBIOME; NONHUMAN; OBESITY; PHAGE THERAPY; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; TOXIN PRODUCTION; BACTERIAL INFECTIONS; DISEASE PREDISPOSITION; DRUG EFFECTS; HOST PATHOGEN INTERACTION; METAGENOME; METAGENOMICS; MICROBIOLOGY; MICROFLORA; RISK FACTOR;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DISEASE SUSCEPTIBILITY; HOST-PATHOGEN INTERACTIONS; HUMANS; METAGENOME; METAGENOMICS; MICROBIOTA; RISK FACTORS;

EID: 84963613854     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-016-0294-z     Document Type: Review

References (180)

1. Kinch MS, Patridge E, Plummer M, Hoyer D. An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov Today. 2014;19:1283-7. doi: 10.1016/j.drudis.2014.07.005.
2. Review on Antimibrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed 5 Apr 2016.
3. Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet. 2003;361:512-9. doi: 10.1016/S0140-6736(03)12489-0.
4. Holmes E, Loo RL, Stamler J, Bictash M, Yap IKS, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453:396-400. doi: 10.1038/nature06882.
5. Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, Cheng J, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science. 2013;339:548-54. doi: 10.1126/science.1229000.
6. Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, et al. Commensal bacteria protect against food allergen sensitization. Proc Natl Acad Sci U S A. 2014;111:13145-50. doi: 10.1073/pnas.1412008111.
7. Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546-51. doi: 10.1021/pr060470d.
8. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451-63. doi: 10.1016/j.cell.2013.11.024.
9. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host Microbe. 2015;18:489-500. doi: 10.1016/j.chom.2015.09.008.
10. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015;17:704-15. doi: 10.1016/j.chom.2015.03.008.
11. Cuthbertson L, Rogers GB, Walker AW, Oliver A, Green LE, Daniels TW, et al. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J. 2015. doi: 10.1038/ismej.2015.198.
12. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods. 2012;9:811-4. doi: 10.1038/nmeth.2066.
13. Abubucker S, Segata N, Goll J, Schubert AM, Izard J, Cantarel BL, et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput Biol. 2012;8:e1002358. doi: 10.1371/journal.pcbi.1002358.
14. Kaminski J, Gibson MK, Franzosa EA, Segata N, Dantas G, Huttenhower C. High-specificity targeted functional profiling in microbial communities with ShortBRED. PLoS Comput Biol. 2015;11:e1004557. doi: 10.1371/journal.pcbi.1004557.
15. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222-7. doi: 10.1038/nature11053.
16. Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature. 2014;510:417-21. doi: 10.1038/nature13421.
17. Hsiao A, Ahmed AMS, Subramanian S, Griffin NW, Drewry LL, Petri WA, et al. Members of the human gut microbiota involved in recovery from Vibrio cholerae infection. Nature. 2014;515:423-6. doi: 10.1038/nature13738.
18. Zackular JP, Baxter NT, Chen GY, Schloss PD. Manipulation of the gut microbiota reveals role in colon tumorigenesis. mSphere. 2015;1:e00001-15. doi: 10.1128/msphere.00001-15.
19. Morgun A, Dzutsev A, Dong X, Greer RL, Sexton DJ, Ravel J, et al. Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut. 2015;64:1732-43. doi: 10.1136/gutjnl-2014-308820.
20. Lichtman JS, Ferreyra JA, Ng KM, Smits SA, Sonnenburg JL, Elias JE. Host-microbiota interactions in the pathogenesis of antibiotic-associated diseases. Cell Rep. 2016;14:1049-61. doi: 10.1016/j.celrep.2016.01.009.
21. Theriot CM, Koenigsknecht MJ, Carlson Jr PE, Hatton GE, Nelson AM, Li B, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114. doi: 10.1038/ncomms4114.
22. Gibson MK, Crofts TS, Dantas G. Antibiotics and the developing infant gut microbiota and resistome. Curr Opin Microbiol. 2015;27:51-6. doi: 10.1016/j.mib.2015.07.007.
23. Hollister EB, Riehle K, Luna RA, Weidler EM, Rubio-Gonzales M, Mistretta TA, et al. Structure and function of the healthy pre-adolescent pediatric gut microbiome. Microbiome. 2015;3:36. doi: 10.1186/s40168-015-0101-x.
24. Lim ES, Zhou Y, Zhao G, Bauer IK, Droit L, Ndao IM, et al. Early life dynamics of the human gut virome and bacterial microbiome in infants. Nat Med. 2015;21:1228-34. doi: 10.1038/nm.3950.
25. Parfrey LW, Walters WA, Knight R. Microbial eukaryotes in the human microbiome: ecology, evolution, and future directions. Front Microbiol. 2011;2:153. doi: 10.3389/fmicb.2011.00153.
26. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med. 2014;6:237ra65. doi: 10.1126/scitranslmed.3008599.
27. Mshvildadze M, Neu J, Shuster J, Theriaque D, Li N, Mai V. Intestinal microbial ecology in premature infants assessed with non-culture-based techniques. J Pediatr. 2010;156:20-5. doi: 10.1016/j.jpeds.2009.06.063.
28. DiGiulio DB, Romero R, Amogan HP, Kusanovic JP, Bik EM, Gotsch F, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One. 2008;3:e3056. doi: 10.1371/journal.pone.0003056.
29. Jimenez E, Fernandez L, Marin ML, Martin R, Odriozola JM, Nueno-Palop C, et al. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol. 2005;51:270-4. doi: 10.1007/s00284-005-0020-3.
30. Martinez de Tejada B. Antibiotic use and misuse during pregnancy and delivery: benefits and risks. Int J Environ Res Public Health. 2014;11:7993-8009. doi: 10.3390/ijerph110807993.
31. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107:1120-38. doi: 10.1097/01.AOG.0000216197.26783.b5.
32. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107:11971-5. doi: 10.1073/pnas.1002601107.
33. Makino H, Kushiro A, Ishikawa E, Kubota H, Gawad A, Sakai T, et al. Mother-to-infant transmission of intestinal bifidobacterial strains has an impact on the early development of vaginally delivered infant's microbiota. PLoS One. 2013;8:e78331. doi: 10.1371/journal.pone.0078331.
34. Centers for Disease Control and Prevention (CDC). Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns-Chicago and Los Angeles County, 2004. MMWR Morb Mortal Wkly Rep. 2006;55:329-32.
35. Roduit C, Scholtens S, de Jongste JC, Wijga AH, Gerritsen J, Postma DS, et al. Asthma at 8 years of age in children born by caesarean section. Thorax. 2009;64:107-13. doi: 10.1136/thx.2008.100875.
36. Bonifacio E, Warncke K, Winkler C, Wallner M, Ziegler AG. Cesarean section and interferon-induced helicase gene polymorphisms combine to increase childhood type 1 diabetes risk. Diabetes. 2011;60:3300-6. doi: 10.2337/db11-0729.
37. Rautava S, Luoto R, Salminen S, Isolauri E. Microbial contact during pregnancy, intestinal colonization and human disease. Nat Rev Gastroenterol Hepatol. 2012;9:565-76. doi: 10.1038/nrgastro.2012.144.
38. La Rosa PS, Warner BB, Zhou Y, Weinstock GM, Sodergren E, Hall-Moore CM, et al. Patterned progression of bacterial populations in the premature infant gut. Proc Natl Acad Sci U S A. 2014;111:12522-7. doi: 10.1073/pnas.1409497111.
39. Verani JR, Schrag SJ. Group B streptococcal disease in infants: progress in prevention and continued challenges. Clin Perinatol. 2010;37:375-92. doi: 10.1016/j.clp.2010.02.002.
40. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. 2011;159:720-5. doi: 10.1016/j.jpeds.2011.05.033.
41. Tanaka S, Kobayashi T, Songjinda P, Tateyama A, Tsubouchi M, Kiyohara C, et al. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. FEMS Immunol Med Microbiol. 2009;56:80-7. doi: 10.1111/j.1574-695X.2009.00553.x.
42. Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr. 2014;165:23-9. doi: 10.1016/j.jpeds.2014.01.010.
43. Moore AM, Ahmadi S, Patel S, Gibson MK, Wang B, Ndao MI, et al. Gut resistome development in healthy twin pairs in the first year of life. Microbiome. 2015;3:27. doi: 10.1186/s40168-015-0090-9.
44. Martin R, Heilig HG, Zoetendal EG, Jimenez E, Fernandez L, Smidt H, et al. Cultivation-independent assessment of the bacterial diversity of breast milk among healthy women. Res Microbiol. 2007;158:31-7. doi: 10.1016/j.resmic.2006.11.004.
45. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-131. doi: 10.1038/nature05414.
46. Sekirov I, Tam NM, Jogova M, Robertson ML, Li Y, Lupp C, et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect Immun. 2008;76:4726-36. doi: 10.1128/iai.00319-08.
47. Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond). 2014;38:1290-8. doi: 10.1038/ijo.2014.119.
48. Gordon JI, Dewey KG, Mills DA, Medzhitov RM. The human gut microbiota and undernutrition. Sci Transl Med. 2012;4:137ps12. doi: 10.1126/scitranslmed.3004347.
49. Chang CY, Trehan I, Wang RJ, Thakwalakwa C, Maleta K, Deitchler M, et al. Children successfully treated for moderate acute malnutrition remain at risk for malnutrition and death in the subsequent year after recovery. J Nutr. 2013;143:215-20. doi: 10.3945/jn.112.168047.
50. Trehan I, Goldbach HS, LaGrone LN, Meuli GJ, Wang RJ, Maleta KM, et al. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med. 2013;368:425-35. doi: 10.1056/NEJMoa1202851.
51. World Health Organization, World Food Programme, United Nations System Standing Committee on Nutrition, The United Nations Children's Fund. Community-based management of severe acute malnutrition. 2007. http://www.who.int/nutrition/topics/Statement_community_based_man_sev_acute_mal_eng.pdf. Accessed 29 Mar 2016.
52. Allen HK, Stanton TB. Altered egos: antibiotic effects on food animal microbiomes. Annu Rev Microbiol. 2014;68:297-315. doi: 10.1146/annurev-micro-091213-113052.
53. Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488:621-6. doi: 10.1038/nature11400.
54. Gough EK, Moodie EE, Prendergast AJ, Johnson SM, Humphrey JH, Stoltzfus RJ, et al. The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g2267. doi: 10.1136/bmj.g2267.
55. Centers for Disease Control and Prevention. Adult obesity facts. 2015. http://www.cdc.gov/obesity/data/adult.html. Accessed 29 Mar 2016.
56. Centers for Disease Control and Prevention. Childhood obesity facts. 2015. http://www.cdc.gov/obesity/data/childhood.html. Accessed 29 Mar 2016.
57. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94:58-65. doi: 10.3945/ajcn.110.010132.
58. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480-4. doi: 10.1038/nature07540.
59. Cox LM, Blaser MJ. Antibiotics in early life and obesity. Nat Rev Endocrinol. 2015;11:182-90. doi: 10.1038/nrendo.2014.210.
60. Mikkelsen KH, Knop FK, Frost M, Hallas J, Pottegard A. Use of antibiotics and risk of type 2 diabetes: a population-based case-control study. J Clin Endocrinol Metab. 2015;100:3633-40. doi: 10.1210/jc.2015-2696.
61. Boursi B, Mamtani R, Haynes K, Yang YX. The effect of past antibiotic exposure on diabetes risk. Eur J Endocrinol. 2015;172:639-48. doi: 10.1530/eje-14-1163.
62. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207-14. doi: 10.1038/nature11234.
63. Raymond F, Ouameur AA, Deraspe M, Iqbal N, Gingras H, Dridi B, et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J. 2016;10:607-20. doi: 10.1038/ismej.2015.148.
64. Clemente JC, Pehrsson EC, Blaser MJ, Sandhu K, Gao Z, Wang B, et al. The microbiome of uncontacted Amerindians. Sci Adv. 2015;1. doi: 10.1126/sciadv.1500183.
65. Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, Leibler S, et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science. 2013;339:91-5. doi: 10.1126/science.1229858.
66. Yurtsev EA, Chao HX, Datta MS, Artemova T, Gore J. Bacterial cheating drives the population dynamics of cooperative antibiotic resistance plasmids. Mol Syst Biol. 2013;9:683. doi: 10.1038/msb.2013.39.
67. De La Cochetiere MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Dore J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol. 2005;43:5588-92. doi: 10.1128/jcm.43.11.5588-5592.2005.
68. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6:e280. doi: 10.1371/journal.pbio.0060280.
69. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4554-61. doi: 10.1073/pnas.1000087107.
70. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5:e9836. doi: 10.1371/journal.pone.0009836.
71. Zaura E, Brandt BW, Teixeira de Mattos MJ, Buijs MJ, Caspers MP, Rashid MU, et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. mBio. 2015;6:e01693-15. doi: 10.1128/mBio.01693-15.
72. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell. 2013;152:39-50. doi: 10.1016/j.cell.2012.10.052.
73. Murray BE, Rensimer ER, DuPont HL. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim-sulfamethoxazole. N Engl J Med. 1982;306:130-5. doi: 10.1056/nejm198201213060302.
74. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1:56-66. doi: 10.1038/ismej.2007.3.
75. Penders J, Stobberingh EE, Savelkoul PH, Wolffs PF. The human microbiome as a reservoir of antimicrobial resistance. Front Microbiol. 2013;4:87. doi: 10.3389/fmicb.2013.00087.
76. Marild K, Ye W, Lebwohl B, Green PH, Blaser MJ, Card T, et al. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. BMC Gastroenterol. 2013;13:109. doi: 10.1186/1471-230x-13-109.
77. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435-8. doi: 10.1086/525047.
78. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2012;80:62-73. doi: 10.1128/iai.05496-11.
79. Centers for Disease Control and Prevention. Antibiotic resistance threats in the united states, 2013. 2013. http://www.cdc.gov/drugresistance/threat-report-2013. Accessed 29 Mar 2016.
80. Higa JT, Kelly CP. New drugs and strategies for management of Clostridium difficile colitis. J Intensive Care Med. 2014;29:190-9.
81. Bassis CM, Theriot CM, Young VB. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agents Chemother. 2014;58:2767-74. doi: 10.1128/aac.02262-13.
82. Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature. 2013;502:96-9. doi: 10.1038/nature12503.
83. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe. 2014;16:770-7. doi: 10.1016/j.chom.2014.11.003.
84. Jump RL, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, et al. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One. 2014;9:e101267. doi: 10.1371/journal.pone.0101267.
85. Zhao Y, Wu J, Li JV, Zhou NY, Tang H, Wang Y. Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res. 2013;12:2987-99. doi: 10.1021/pr400263n.
86. Yap IK, Li JV, Saric J, Martin FP, Davies H, Wang Y, et al. Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res. 2008;7:3718-28. doi: 10.1021/pr700864x.
87. Romick-Rosendale LE, Goodpaster AM, Hanwright PJ, Patel NB, Wheeler ET, Chona DL, et al. NMR-based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad-spectrum antibiotic enrofloxacin (Baytril). Magn Reson Chem. 2009;47 Suppl 1:S36-46. doi: 10.1002/mrc.2511.
88. Antunes LC, Han J, Ferreira RB, Lolic P, Borchers CH, Finlay BB. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother. 2011;55:1494-503. doi: 10.1128/aac.01664-10.
89. Zheng X, Xie G, Zhao A, Zhao L, Yao C, Chiu NH, et al. The footprints of gut microbial-mammalian co-metabolism. J Proteome Res. 2011;10:5512-22. doi: 10.1021/pr2007945.
90. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517:205-8. doi: 10.1038/nature13828.
91. Knoop KA, McDonald KG, Kulkarni DH, Newberry RD. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut. 2015. doi: 10.1136/gutjnl-2014-309059.
92. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044-9. doi: 10.1016/j.cgh.2011.08.014.
93. Alekshun MN, Levy SB. Targeting virulence to prevent infection: to kill or not to kill? Drug Discov Today Ther Strateg. 2004;1:483-9. doi: 10.1016/j.ddstr.2004.10.006.
94. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol. 2008;6:17-27. doi: 10.1038/nrmicro1818.
95. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 2010;9:117-28. doi: 10.1038/nrd3013.
96. Zambelloni R, Marquez R, Roe AJ. Development of antivirulence compounds: a biochemical review. Chem Biol Drug Des. 2015;85:43-55. doi: 10.1111/cbdd.12430.
97. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol. 2001;55:165-99. doi: 10.1146/annurev.micro.55.1.165.
98. Suga H, Smith KM. Molecular mechanisms of bacterial quorum sensing as a new drug target. Curr Opin Chem Biol. 2003;7:586-91.
99. Dong YH, Wang LH, Xu JL, Zhang HB, Zhang XF, Zhang LH. Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature. 2001;411:813-7. doi: 10.1038/35081101.
100. Rasmussen TB, Manefield M, Andersen JB, Eberl L, Anthoni U, Christophersen C, et al. How Delisea pulchra furanones affect quorum sensing and swarming motility in Serratia liquefaciens MG1. Microbiology. 2000;146:3237-44. doi: 10.1099/00221287-146-12-3237.
101. Manefield M, Rasmussen TB, Henzter M, Andersen JB, Steinberg P, Kjelleberg S, et al. Halogenated furanones inhibit quorum sensing through accelerated LuxR turnover. Microbiology. 2002;148:1119-27. doi: 10.1099/00221287-148-4-1119.
102. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR, et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology. 2002;148:87-102. doi: 10.1099/00221287-148-1-87.
103. Smith M, Moon H, Chowrira G, Kunst L. Heterologous expression of a fatty acid hydroxylase gene in developing seeds of Arabidopsis thaliana. Planta. 2003;217:507-16. doi: 10.1007/s00425-003-1015-6.
104. Smith KM, Bu Y, Suga H. Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthetic autoinducer analogs. Chem Biol. 2003;10:81-9.
105. Starkey M, Lepine F, Maura D, Bandyopadhaya A, Lesic B, He J, et al. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog. 2014;10:e1004321. doi: 10.1371/journal.ppat.1004321.
106. Maeda T, Garcia-Contreras R, Pu M, Sheng L, Garcia LR, Tomas M, et al. Quorum quenching quandary: resistance to antivirulence compounds. ISME J. 2012;6:493-501. doi: 10.1038/ismej.2011.122.
107. Garcia-Contreras R, Martinez-Vazquez M, Velazquez Guadarrama N, Villegas Paneda AG, Hashimoto T, Maeda T, et al. Resistance to the quorum-quenching compounds brominated furanone C-30 and 5-fluorouracil in Pseudomonas aeruginosa clinical isolates. Pathog Dis. 2013;68:8-11. doi: 10.1111/2049-632x.12039.
108. Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol. 2014;12:300-8. doi: 10.1038/nrmicro3232.
109. Bender KO, Garland M, Ferreyra JA, Hryckowian AJ, Child MA, Puri AW, et al. A small-molecule antivirulence agent for treating Clostridium difficile infection. Sci Transl Med. 2015;7:306ra148. doi: 10.1126/scitranslmed.aac9103.
110. Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A. 2005;102:7958-63. doi: 10.1073/pnas.0502159102.
111. Karginov VA, Nestorovich EM, Moayeri M, Leppla SH, Bezrukov SM. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Proc Natl Acad Sci U S A. 2005;102:15075-80. doi: 10.1073/pnas.0507488102.
112. Armstrong GD, Rowe PC, Goodyer P, Orrbine E, Klassen TP, Wells G, et al. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis. 1995;171:1042-5.
113. Report of The Lancet Special Commission on the relative strengths of diphtheria antitoxic serums. Lancet. 1896;148:182-95. doi: 10.1016/S0140-6736(01)72399-9.
114. Lopez EL, Contrini MM, Glatstein E, Gonzalez Ayala S, Santoro R, Allende D, et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:239-43. doi: 10.1128/aac.00343-09.
115. Yamagami S, Motoki M, Kimura T, Izumi H, Takeda T, Katsuura Y, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001;184:738-42. doi: 10.1086/323082.
116. Chen Z, Moayeri M, Zhou YH, Leppla S, Emerson S, Sebrell A, et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis. 2006;193:625-33. doi: 10.1086/500148.
117. Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science. 2005;310:670-4. doi: 10.1126/science.1116739.
118. Shakhnovich EA, Hung DT, Pierson E, Lee K, Mekalanos JJ. Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci U S A. 2007;104:2372-7. doi: 10.1073/pnas.0611643104.
119. Felise HB, Nguyen HV, Pfuetzner RA, Barry KC, Jackson SR, Blanc MP, et al. An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe. 2008;4:325-36. doi: 10.1016/j.chom.2008.08.001.
120. Wang D, Zetterstrom CE, Gabrielsen M, Beckham KS, Tree JJ, Macdonald SE, et al. Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds. J Biol Chem. 2011;286:29922-31. doi: 10.1074/jbc.M111.233858.
121. Kline T, Felise HB, Barry KC, Jackson SR, Nguyen HV, Miller SI. Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial type III secretion. J Med Chem. 2008;51:7065-74. doi: 10.1021/jm8004515.
122. Veenendaal AK, Sundin C, Blocker AJ. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol. 2009;191:563-70. doi: 10.1128/jb.01004-08.
123. Muschiol S, Bailey L, Gylfe A, Sundin C, Hultenby K, Bergstrom S, et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A. 2006;103:14566-71. doi: 10.1073/pnas.0606412103.
124. Bailey L, Gylfe A, Sundin C, Muschiol S, Elofsson M, Nordstrom P, et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 2007;581:587-95. doi: 10.1016/j.febslet.2007.01.013.
125. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol. 2003;10:241-9.
126. Smith MA, Coincon M, Paschos A, Jolicoeur B, Lavallee P, Sygusch J, et al. Identification of the binding site of Brucella VirB8 interaction inhibitors. Chem Biol. 2012;19:1041-8. doi: 10.1016/j.chembiol.2012.07.007.
127. Greene SE, Pinkner JS, Chorell E, Dodson KW, Shaffer CL, Conover MS, et al. Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli. mBio. 2014;5:e02038. doi: 10.1128/mBio.02038-14.
128. Pinkner JS, Remaut H, Buelens F, Miller E, Aberg V, Pemberton N, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci U S A. 2006;103:17897-902. doi: 10.1073/pnas.0606795103.
129. Berg V, Sellstedt M, Hedenstrom M, Pinkner JS, Hultgren SJ, Almqvist F. Design, synthesis and evaluation of peptidomimetics based on substituted bicyclic 2-pyridones-targeting virulence of uropathogenic E. coli. Bioorg Med Chem. 2006;14:7563-81. doi: 10.1016/j.bmc.2006.07.017.
130. Svensson A, Larsson A, Emtenas H, Hedenstrom M, Fex T, Hultgren SJ, et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem. 2001;2:915-8.
131. Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science. 2008;319:1391-4. doi: 10.1126/science.1153018.
132. de la Fuente-Núñez C, Reffuveille F, Haney EF, Straus SK, Hancock REW. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog. 2014;10:e1004152. doi: 10.1371/journal.ppat.1004152.
133. Ross-Gillespie A, Weigert M, Brown SP, Kummerli R. Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment. Evol Med Public Health. 2014;2014:18-29. doi: 10.1093/emph/eou003.
134. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506-14. doi: 10.1038/nrgastro.2014.66.
135. McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014;4, e005047. doi: 10.1136/bmjopen-2014-005047.
136. Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012;157:878-88. doi: 10.7326/0003-4819-157-12-201212180-00563.
137. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;CD004827. doi: 10.1002/14651858.CD004827.pub3
138. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Alimentary Pharmacol Therapeut. 2012;35:1355-69. doi: 10.1111/j.1365-2036.2012.05104.x.
139. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959-69. doi: 10.1001/jama.2012.3507.
140. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;CD003048. doi: 10.1002/14651858.CD003048.pub3.
141. Lievin-Le Moal V, Servin AL. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev. 2014;27:167-99. doi: 10.1128/cmr.00080-13.
142. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A. 2007;104:7617-21. doi: 10.1073/pnas.0700440104.
143. Cimperman L, Bayless G, Best K, Diligente A, Mordarski B, Oster M, et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol. 2011;45:785-9. doi: 10.1097/MCG.0b013e3182166a42.
144. Taipale T, Pienihakkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105:409-16. doi: 10.1017/s0007114510003685.
145. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1012-8. doi: 10.1002/ibd.20377.
146. Tannock GW, Tiong IS, Priest P, Munro K, Taylor C, Richardson A, et al. Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities. J Med Microbiol. 2011;60:366-70. doi: 10.1099/jmm.0.025874-0.
147. Geldart K, Borrero J, Kaznessis YN. Chloride-inducible expression vector for delivery of antimicrobial peptides targeting antibiotic-resistant Enterococcus faecium. Appl Environ Microbiol. 2015;81:3889-97. doi: 10.1128/aem.00227-15.
148. Pereira VB, Saraiva TD, Souza BM, Zurita-Turk M, Azevedo MS, De Castro CP, et al. Development of a new DNA vaccine based on mycobacterial ESAT-6 antigen delivered by recombinant invasive Lactococcus lactis FnBPA+. Appl Microbiol Biotechnol. 2015;99:1817-26. doi: 10.1007/s00253-014-6285-3.
149. Gupta S, Bram EE, Weiss R. Genetically programmable pathogen sense and destroy. ACS Syn Bio. 2013;2:715-23. doi: 10.1021/sb4000417.
150. Hwang IY, Tan MH, Koh E, Ho CL, Poh CL, Chang MW. Reprogramming microbes to be pathogen-seeking killers. ACS Synth Biol. 2014;3:228-37. doi: 10.1021/sb400077j.
151. Yaung SJ, Deng L, Li N, Braff JL, Church GM, Bry L, et al. Improving microbial fitness in the mammalian gut by in vivo temporal functional metagenomics. Mol Syst Biol. 2015;11:788. doi: 10.15252/msb.20145866.
152. Stripling J, Kumar R, Baddley JW, Nellore A, Dixon P, Howard D, et al. Loss of vancomycin-resistant Enterococcus fecal dominance in an organ transplant patient with Clostridium difficile colitis after fecal microbiota transplant. Open Forum Infect Dis. 2015;2:ofv078. doi: 10.1093/ofid/ofv078.
153. Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-43. doi: 10.1111/apt.13144.
154. Wyatt JP. Oxford handbook of emergency medicine. Oxford: Oxford University Press; 2006.
155. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45:649-59. doi: 10.1128/aac.45.3.649-659.2001.
156. Khalifa L, Brosh Y, Gelman D, Coppenhagen-Glazer S, Beyth S, Poradosu-Cohen R, et al. Targeting Enterococcus faecalis biofilms with phage therapy. Appl Environ Microbiol. 2015;81:2696-705. doi: 10.1128/aem.00096-15.
157. Kong M, Ryu S. Bacteriophage PBC1 and its endolysin as an antimicrobial agent against Bacillus cereus. Appl Environ Microbiol. 2015;81:2274-83. doi: 10.1128/aem.03485-14.
158. Olszak T, Zarnowiec P, Kaca W, Danis-Wlodarczyk K, Augustyniak D, Drevinek P, et al. In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients. Appl Microbiol Biotechnol. 2015;99:6021-33. doi: 10.1007/s00253-015-6492-6.
159. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol. 1987;133:1111-26. doi: 10.1099/00221287-133-5-1111.
160. Filippov AA, Sergueev KV, He Y, Huang XZ, Gnade BT, Mueller AJ, et al. Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice. PLoS One. 2011;6:e25486. doi: 10.1371/journal.pone.0025486.
161. Citorik RJ, Mimee M, Lu TK. Bacteriophage-based synthetic biology for the study of infectious diseases. Curr Opin Microbiol. 2014;19:59-69. doi: 10.1016/j.mib.2014.05.022.
162. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A. 2007;104:11197-202. doi: 10.1073/pnas.0704624104.
163. Pei R, Lamas-Samanamud GR. Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl Environ Microbiol. 2014;80:5340-8. doi: 10.1128/aem.01434-14.
164. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32:1146-50. doi: 10.1038/nbt.3043.
165. Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014;32:1141-5. doi: 10.1038/nbt.3011.
166. Yosef I, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci U S A. 2015;112:7267-72. doi: 10.1073/pnas.1500107112.
167. Gipponi M, Sciutto C, Accornero L, Bonassi S, Raso C, Vignolo C, et al. Assessing modifications of the intestinal bacterial flora in patients on long-term oral treatment with bacampicillin or amoxicillin: a random study. Chemioterapia. 1985;4:214-7.
168. Hernandez E, Bargiela R, Diez MS, Friedrichs A, Perez-Cobas AE, Gosalbes MJ, et al. Functional consequences of microbial shifts in the human gastrointestinal tract linked to antibiotic treatment and obesity. Gut Microbes. 2013;4:306-15. doi: 10.4161/gmic.25321.
169. Sunakawa K, Akita H, Iwata S, Sato Y. The influence of cefotaxime on intestinal flora and bleeding diathesis in infants and neonates, compared with other beta-lactams. J Antimicrob Chemother. 1984;14 Suppl B:317-24.
170. Lambert-Zechovsky N, Bingen E, Aujard Y, Mathieu H. Impact of cefotaxime on the fecal flora in children. Infection. 1985;13 Suppl 1:S140-4.
171. Brismar B, Edlund C, Malmborg AS, Nord CE. Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1990;34:481-3.
172. Kager L, Liljeqvist L, Malmborg AS, Nord CE. Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1981;20:736-40.
173. Brismar B, Edlund C, Nord CE. Comparative effects of clarithromycin and erythromycin on the normal intestinal microflora. Scand J Infect Dis. 1991;23:635-42.
174. Bergan T, Nord CE, Thorsteinsson SB. Effect of meropenem on the intestinal microflora. Eur J Clin Microbiol Infect Dis. 1991;10:524-7.
175. Nord CE, Bergan T, Thorsteinsson SB. Impact of ticarcillin/clavulanate on the intestinal microflora. J Antimicrob Chemother. 1989;24 Suppl B:221-6.
176. Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother. 2006;50:3375-80. doi: 10.1128/aac.00373-06.
177. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014;60:824-31. doi: 10.1016/j.jhep.2013.11.034.
178. Prudhomme M, Attaiech L, Sanchez G, Martin B, Claverys JP. Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae. Science. 2006;313:89-92. doi: 10.1126/science.1127912.
179. Shevchuk YM, Pharm D, Conly JM. Antibiotic-associated hypoprothrombinemia. Infect Dis Newsl. 1992;11:43-6. doi: 10.1016/0278-2316(92)90002-U.
180. Perez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2013;62:1591-601. doi: 10.1136/gutjnl-2012-303184.